Johnson & Johnson (JNJ) Gains from Sales and Divestitures (2010 - 2012)

Johnson & Johnson's (JNJ) quarterly Gains from Sales and Divestitures came in at $8.3 million in Q1 2012, up 31.81% year-on-year from $6.3 million in Q1 2011, and up 31.81% quarter-over-quarter from $6.3 million in Q1 2011.

Johnson & Johnson (JNJ) Gains from Sales and Divestitures (2010 - 2012) Analysis & Trends

Johnson & Johnson has disclosed Gains from Sales and Divestitures across 3 years of filings, most recently posting $8.3 million for Q1 2012.

  • Gains from Sales and Divestitures for Q1 2012 came in at $8.3 million, up 31.81% year-over-year; the trailing twelve-month figure through Jan 2012 was $8.3 million (up 31.81% YoY), and the FY2012 annual result was $8.3 million, up 31.81% from the prior year.
  • Gains from Sales and Divestitures came in at $8.3 million for Q1 2012 at Johnson & Johnson, up from $6.3 million in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $8.3 million in Q1 2012 to a low of $5.7 million in Q1 2010.
  • The 3-year median for Gains from Sales and Divestitures is $6.3 million (2011), against an average of $6.8 million.
  • Across the five-year window, Gains from Sales and Divestitures climbed 10.2% in 2011 and soared 31.81% in 2012, its largest moves.
  • Johnson & Johnson's Gains from Sales and Divestitures stood at $5.7 million in 2010, then grew by 10.2% to $6.3 million in 2011, then soared by 31.81% to $8.3 million in 2012.
  • The last three Gains from Sales and Divestitures figures came in at $8.3 million (Q1 2012), $6.3 million (Q1 2011), and $5.7 million (Q1 2010), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 96,436,181.12 Bn 96,436,176.16 Bn 7.76 Bn
2 Eli Lilly 1,017.30 Bn 1,012.01 Bn 16.22 Bn
3 Johnson & Johnson 579.61 Bn 557.55 Bn 15.96 Bn
4 AbbVie 402.30 Bn 392.96 Bn 10.78 Bn
5 Merck 294.24 Bn 288.59 Bn 12.09 Bn
6 Amgen 191.82 Bn 179.78 Bn 5.87 Bn
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn
8 Pfizer 149.05 Bn 136.28 Bn -1.21 Bn
9 Bristol Myers Squibb 116.33 Bn 105.88 Bn 8.07 Bn
10 Novartis Ag 112.59 Bn 111.90 Bn -

Historic Data

Download Data
DateValue
Jan 1, 2012 8.30 Mn
Jan 1, 2012 8.30 Mn
Jan 2, 2011 6.30 Mn
Jan 2, 2011 6.30 Mn
Jan 3, 2010 5.71 Mn
Jan 3, 2010 5.71 Mn